## AZN: AstraZeneca PLC - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 0.2% below STRENGTH zone (3.0-6.0%); PEG 1.07 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($90.12)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 4
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. Valicenti Advisory Services Inc. Has $4.66 Million Holdings in AstraZeneca PLC $AZN**
- Source: MarketBeat | 20251228T120923 | Bullish | Relevance: 100%
- Valicenti Advisory Services Inc. (VASI) significantly reduced its stake in AstraZeneca PLC (NASDAQ:AZN) by 20.1% in the third quarter, now holding 60,696 shares valued at approximately $4.66 million. This position represents about 1.0% of VASI's investment portfolio. Despite other institutional investors increasing their holdings, AstraZeneca recently surpassed quarterly earnings and revenue estimates and maintains a "Moderate Buy" consensus rating from Wall Street analysts.

**2. Robbins Farley Purchases 27,582 Shares of AstraZeneca PLC $AZN**
- Source: MarketBeat | 20251225T120858 | Bullish | Relevance: 100%
- Robbins Farley significantly increased its holdings in AstraZeneca PLC (NASDAQ:AZN) by 103.8% in Q3, acquiring an additional 27,582 shares to hold a total of 54,149 shares valued at $4.154 million. This move positions AZN as the firm's 29th largest holding, comprising about 1.7% of its portfolio. Several other institutional investors also substantially boosted their stakes, contributing to hedge funds and institutional investors now owning approximately 20.35% of AstraZeneca stock.

**3. AstraZeneca Reaches Settlement With MSN Labs Over Cancer Drug**
- Source: Bloomberg Law News | 20251224T200922 | Neutral | Relevance: 100%
- AstraZeneca Plc has settled a patent infringement dispute with MSN Laboratories Pvt Ltd. concerning its blood-cancer drug, Calquence. The settlement, formalized by a federal court in Delaware, enjoins MSN from infringing specific patents related to the drug's active ingredient, acalabrutinib maleate. The lawsuit alleged that MSN's tablets infringed two of AstraZeneca's patents for Calquence.

**4. Swedbank AB Buys 286,904 Shares of AstraZeneca PLC $AZN**
- Source: MarketBeat | 20251224T140922 | Bullish | Relevance: 100%
- Swedbank AB increased its holdings in AstraZeneca PLC by 7.0% in the third quarter, purchasing an additional 286,904 shares to own a total of 4,364,458 shares, valued at approximately $334.84 million. AstraZeneca has shown strong financial performance, beating earnings estimates with $1.19 EPS and revenue of $15.19 billion, and analysts maintain a positive outlook with a "Moderate Buy" rating. The company's stock currently has a market capitalization of $285.77 billion and a price-to-earnings ratio of 30.61.

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 10.3% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 6 |

**Top Holders:**
- Price (T.Rowe) Assoc: 1.9% (-5.4%)
- Primecap Management : 1.5% (-3.3%)
- Bank of America Corp: 1.2% (+4.7%)
- Wellington Managemen: 1.2% (-5.9%)
- Capital Internationa: 0.9% (-20.2%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.07 suggests fair value with growth premium. Quality metrics strong (ROE 22%, margin 16%). Balance sheet: $4.4B free cash flow. Institutional flow bearish (6 selling vs 4 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $288.0B |
| Beta | 0.17 |
| 52W Range | $61.24 - $94.02 |
| Short Interest | 0.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.07 |
| Forward P/E | 18.0 |
| Current P/E | 20.2 |
| YoY Growth | 12.1% |
| EPS Direction | STABLE |

### Technicals

MRS_10 stable at 0.2% (minimal 5-day change). Below STRENGTH zone by 2.8pp (needs >3.0% for momentum thesis). MRS_5 at 0.5% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). OFD pattern: +SLL (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 0.23% (CS: 79) | Neutral |
| RSI_14 | 62.1 | Neutral |
| MACD Histogram | -0.02 | Bearish |
| vs SMA20 | 1.020x | Above |
| vs SMA50 | 1.055x | Above |
| vs SMA200 | 1.199x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $92.90
- **Stop Loss:** $90.12 (3.0% risk)
- **Target:** $95.68 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 474
- **Position Value:** $44,034.60
- **Portfolio %:** 44.03%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with selective risk appetite amid holiday trading. VIX at extreme lows (13.6) signals complacency while positive yield curve (+59bps) and stable economic data support continuation. Focus on quality names with AI/infrastructure exposure while monitoring January volatility reset.*

### Earnings

**Next:** 2026-02-10 (Est: $1.09)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.13 | $1.19 | +4.9% |
| 2025Q2 | $1.46 | $1.08 | -25.9% |
| 2025Q1 | $1.12 | $1.25 | +11.6% |
| 2024Q4 | $1.04 | $1.04 | +0.8% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*